Detalhe da pesquisa
1.
Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma.
Am J Hematol
; 2024 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38700035
2.
The physical exam's role in determining dose-limiting toxicity prior to immunochemotherapy administration in lymphoma.
J Oncol Pharm Pract
; 29(3): 601-602, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35105218
3.
Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies.
Blood
; 133(16): 1742-1752, 2019 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-30803990
4.
Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.
Blood
; 132(3): 293-306, 2018 07 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29695516
5.
Multicentre retrospective study of intravascular large B-cell lymphoma treated at academic institutions within the United States.
Br J Haematol
; 186(2): 255-262, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31044423
6.
Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs.
Oncologist
; 24(11): e1236-e1250, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31346132
7.
COVID-19 infection outcomes in patients receiving CD20 targeting T-cell engaging bispecific antibodies for B-cell non-Hodgkin lymphoma.
Ann Hematol
; 102(9): 2635-2637, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37294440
8.
Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL).
Am J Hematol
; 93(3): 394-400, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29194714
9.
Taking a BiTE out of Lymphoma: Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma.
Cancers (Basel)
; 16(9)2024 Apr 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38730677
10.
A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204).
Blood Adv
; 8(4): 867-877, 2024 Feb 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-38113459
11.
Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma.
Blood Adv
; 7(16): 4518-4527, 2023 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-37013954
12.
Long-term outcomes of second-line versus later-line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis.
Cancer Med
; 12(18): 18643-18653, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37705497
13.
Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study.
Blood Adv
; 7(20): 6055-6065, 2023 10 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37581593
14.
Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium.
J Hematol Oncol
; 16(1): 122, 2023 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38104096
15.
Divergent paths: management of early relapsed follicular lymphoma.
Hematology Am Soc Hematol Educ Program
; 2022(1): 666-675, 2022 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36485106
16.
Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?
Clin Lymphoma Myeloma Leuk
; 21(1): 8-20.e3, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33132100
17.
Germline variants discovered in lymphoma patients undergoing tumor profiling: a case series.
Fam Cancer
; 20(1): 61-65, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32504211
18.
Evaluating the Role of Novel Oncology Agents: Oncology Stewardship in Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Clin Lymphoma Myeloma Leuk
; 21(5): 295-308, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33485834
19.
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma.
Blood Adv
; 5(12): 2577-2585, 2021 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34152395
20.
Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkin's lymphoma.
Leuk Lymphoma
; 62(13): 3138-3146, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34263702